- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00325793
IV Double and Triple Concentrated Nicardipine for Stroke and ICH
An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage
Study Overview
Detailed Description
Hypertension can often cause neurological worsening in patients with either ICH or SAH. Hypertension has been related to increased incidence of intracranial hemorrhage in patients who are treated with thrombolytics or on anticoagulation. Timely control of hypertension is directly related to the outcome of these patients. Furthermore, unlike in the conditions of hypertensive emergency or urgency, gentle titration to control the blood pressure is recommended in patients with either ischemic cerebral infarction or hemorrhage. Therefore the ideal agent to control hypertension in these patients would have these characteristics:
- Rapid onset of action
- Predictable dose response
- Titratable to desired BP
- Minimal dosage adjustments
- Minimal adverse effects
- No increase in INTRACRANIAL PRESSURE (ICP)
- Easy transition to oral formulation for long-term maintenance
Currently, only IV sodium nitroprusside, nitroglycerine, enalapril and esmolol are used for controlling blood pressure in patients with IS, ICH and SAH. These agents are difficult to titrate and may potentially be harmful to brain cells.
Nicardipine offers several advantages in blood pressure control. It may cause dilatation of the coronary vessels while has no effect on cardiac conduction. It is not associated with coronary steal. As the only IV calcium channel blocker approved for the treatment of hypertension, nicardipine is vasoselective, and has a rapid onset and precisely controllable in a variety of patient types. It is as effective as sodium nitroprusside with fewer dose adjustments. It has documented safety with a low incidence of side effects. It requires minimal dose adjustments.
The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). In patients with ischemic cerebral stroke (IS) or hemorrhage (ICH), intravenous infusion of large volume can contribute to cerebral edema or increase in intracranial pressure (ICP). If the infusion of nicardipine can be double or triple concentrated without the need of a central line, it not only offers titratable BP control, but also less overall volume to infuse the drug.
This is a phase IV prospective, open-label, dose regimen study of double or triple concentration nicardipine infusion for controlling blood pressure in patients with either ischemic cerebral infarction (IS) or intracerebral hemorrhage (ICH) or subarachnoid hemorrhage (SAH). Once the patient has the need for rapid control of blood pressure, he or she will be eligible for the study. The first 25 patients will be consented for the double dose treatment and the next 25 patients will be consented for the triple dose treatment. The patient will be followed during the infusion period for efficacy and safety.
Study Type
Enrollment
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: David Wang, DO
- Phone Number: 309-624-9500
- Email: dwang@uic.edu
Study Locations
-
-
Illinois
-
Peoria, Illinois, United States, 61637
- Recruiting
- OSF Stroke Center
-
Principal Investigator:
- David Wang, DO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males or females, 18 years of age or older.
- Acute ischemic cerebral stroke (IS) with uncontrollable hypertension that may need to be controlled for the purpose of considering thrombolytic therapy or anticoagulation therapy.
- Intracerebral hemorrhagic (ICH) stroke patients, including subarachnoid hemorrhage (SAH) (surgically treated or not), any territory with an appropriate study (head CT scan or MRI scan) providing results consistent with this diagnosis, who may require the control of hypertension or control of blood pressure.
Exclusion Criteria:
- Allergy to Nicardipine or known hypersensitivity to Nicardipine.
- Chronic renal failure or Creatinine blood sample levels> 2.0.
- Impaired hepatic function defined as a two times value of liver enzymes.
- Severe left ventricular dysfunction defined as ventricular ejection fraction < 30%.
- Patients or authorized representative who refused be enrolled into this study.
- Advanced aortic stenosis.
- Pregnant or nursing women will not be enrolled in this study.
- No patient will be allowed to be enrolled in this study more than once.
- Patients may not be enrolled into other clinical studies during their involvement with this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
• Demonstrate the feasibility and safety of double and triple concentrated peripheral intravenous Nicardipine for patients in the Neuroscience Critical Care Unit.
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety
|
Time and dosage adjustment needed to reach the target BP range
|
To evaluate the tolerance of the double or triple concentrated Nicardipine
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Wang, DO, OSF Stroke Center
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0012003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
Clinical Trials on Nicardipine
-
University of MinnesotaMedical University of South Carolina; Johns Hopkins University; National Institute... and other collaboratorsTerminatedIntracerebral HemorrhageUnited States, Taiwan, Korea, Republic of, Germany, Japan, Canada, China
-
University of MinnesotaNational Institute of Neurological Disorders and Stroke (NINDS)CompletedStroke | Hypertension | Intracerebral HemorrhageUnited States
-
Astellas Pharma China, Inc.CompletedHypertension Emergency | End-organ DamageChina
-
University of Illinois at ChicagoCompletedSubarachnoid Hemorrhage | Intracerebral HemorrhageUnited States
-
The Cleveland ClinicEKR Therapeutics, IncCompletedHypertensive UrgencyUnited States
-
The Affiliated Hospital Of Guizhou Medical UniversityNot yet recruitingAneurysmal Subarachnoid Hemorrhage | Vasospasm
-
The Medicines CompanyCompletedHypertensionUnited States
-
University of FloridaTerminated
-
Yonsei UniversityActive, not recruitingIschemic StrokeKorea, Republic of
-
Peng Roc Chen, MDYale University; Northwell Health; University of Michigan; University of Illinois... and other collaboratorsRecruiting